Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 1093

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 1093
---
 First Offer Agreement, dated July3, 2024, between TuHURA Biosciences, Inc. and Kineta, Inc. (incorporated by reference to Exhibit 10.41 to the Registration Statement on FormS-4/Afiled on July19, 2024 (Registration No.333-279368))10.15Form of Secured Promissory Note (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on February 14, 2025)10.16Clinical Trial Funding Agreement, dated December 11, 2024, between TuHURA Biosciences, Inc. and Kineta, Inc. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on December 12, 2024)10.17#Form of TuHURA Biosciences, Inc. Stock Option Agreement under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on November 15, 2024)10.18#TuHURA Biosciences, Inc. 2025 Non-Employee director Compensation Program (incorporated by reference to Exhibit 10.18 to the Annual Report on Form 10-K filed with the SEC on March 31, 2025)21.1List of Subsidiaries (incorporated by reference to Exhibit 21.1 to TuHURA Biosciences, Inc’s Current Report on Form8-Kfiled with the SEC on October21, 2024)23.1*Consent of Marcum, LLP, independent registered public accounting firm of Kineta, Inc.23.2*Consent of Cherry Bekaert, LLP, independent registered public accounting firm of TuHURA Biosciences, Inc.23.3*Consent of Marcum, LLP, independent registered public accounting firm of TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.)23.4*Consent of Foley & Lardner LLP (included in Exhibit 5.1)23.5**Consent of Orrick, Herrington & SutcliffeLLP (included in Exhibit 8.2)24.1***Power of Attorney (included on the signature page of the Registration Statement)99.